How the IRA Is Reshaping Biosimilar Adoption

Generics represent 52.2% in ambulances and biosimilars 82% in hospitals. Vaccines lead to spending in primary care, with a strong increase in meningocococococo and influenza.

How the IRA is Reshaping Biosimilar Adoption

Panelists discuss how the Inflation Reduction Act (IRA) of 2022 has influenced biosimilar utilization in the US health care system through its pharmacy provisions targeting Medicare patients, examining institutional impacts on adoption patterns, exploring payer preferences between high- and low-wholesale acquisition cost (WAC) therapies under the new regulatory framework, forecasting the evolving role of biosimilars at health care institutions, …